As with all anti-TNF-a therapies, golimumab increases patients’ risk of upper respiratory tract infections, sinusitis, bronchitis, viral infections, and fungal infections as a result of their systemic immunosuppressive effects [1]. The gene discussed is TNF; the disease is fungal infectious disease.